Ethereum's staked ETH is shifting to newer 0x02 validators, now holding 40% of all staked ETH after the Pectra hard fork in May 2025. This upgrade allows validators to stake up to 2,048 ETH, enabling reward compounding and reducing the validator count from about 880,000 to an estimated 628,000. Lido, a major staking protocol, has consolidated over 8 million ETH into fewer validators, increasing its share of 0x02 staked ETH to 52%. The network expects reduced load and attestation traffic, while upcoming modules aim to broaden validator participation and improve security.
The story on Lido's ETH staking update is presented with Pluang market data for context. As of Oct 13, 2026 21:51 WIB, 15 of 50 major cryptocurrencies on Pluang rose while 34 fell. Notable movers include COTI at Rp226 with a 1-day change of -4.04%, XNO at Rp5.854 with 0% Sell / 100% Buy order activity, and MANA at Rp1.641 with a 1-day change of -3.87%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
